- Home
- CRSP vs BOOT Comparison
CRSP vs BOOT Comparison
Compare CRSP & BOOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRSP | BOOT |
|---|---|---|
| Founded | 2013 | 1978 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.7B |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRSP | BOOT |
|---|---|---|
| Price | $52.09 | $145.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | $70.29 | ★ $223.09 |
| AVG Volume (30 Days) | ★ 1.3M | 525.7K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | N/A | ★ 2.29 |
| Revenue | $289,590,000.00 | ★ $776,854,000.00 |
| Revenue This Year | $807.72 | $19.98 |
| Revenue Next Year | $172.52 | $13.91 |
| P/E Ratio | ★ N/A | $62.45 |
| Revenue Growth | ★ 9169.85 | 14.59 |
| 52 Week Low | $44.12 | $133.18 |
| 52 Week High | $78.48 | $210.25 |
Technical Indicators
Market Signals| Indicator | CRSP | BOOT |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 35.36 |
| Support Level | $50.45 | $135.35 |
| Resistance Level | $60.41 | $169.60 |
| Average True Range (ATR) | 2.27 | 5.32 |
| MACD | -0.79 | -1.63 |
| Stochastic Oscillator | 4.25 | 5.67 |
Price Performance
Historical ComparisonAbout CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores that sell western and work boots and related apparel and accessories. The Company operates retail locations throughout the U.S. and sells its merchandise via the Internet. The Company operates a total of approximately 539 stores in 49 states. All stores operated under the Boot Barn name.